newsfilter
← Latest News
ACCESS Newswire·

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

MIRA
  • MIRA Pharmaceuticals announced new preclinical data showing Mira-55 did not produce cannabinoid-like central nervous system side effects in behavioral assays.
  • The drug's profile was differentiated from Δ9-tetrahydrocannabinol (THC) & the CB1 antagonist rimonabant across tests for hypothermia, catalepsy, anxiety, & motor function.
  • No psychogenic effects, sedation, or motor impairment were observed at oral doses of 10, 30, or 100 mg/kg.
  • Mira-55 demonstrated reduced anxiety-like behavior in the Elevated Plus Maze, whereas rimonabant induced anxiety-like changes.
  • Previous data confirmed Mira-55 delivers morphine-comparable pain relief in inflammatory pain models without opioid-related risks.
  • These findings support the company's plan to submit an Investigational New Drug (IND) application for inflammatory pain.
  • Mira-55 is a next-generation cannabinoid analog designed to minimize CB1-mediated psychoactivity while modulating CB1 & CB2 receptors.
  • The U.S. Drug Enforcement Administration (DEA) determined Mira-55 is not classified as a controlled substance.
  • The drug targets the global non-opioid pain treatment market, projected to grow from $45.3 billion in 2024 to $70.3 billion by 2030.
  • Current treatment alternatives include opioids with dependence risks & NSAIDs with gastrointestinal, renal, or cardiovascular adverse effects.
  • MIRA is advancing Mira-55 toward regulatory IND-enabling studies to address significant unmet medical needs in pain management.